Skip to content
Screener

4D Molecular Therapeutics FDMT Q3 2025 earnings

Reported November 10, 2025 · Before market open

Revenue$90.0KMiss by $30.8M
EPS-$1.01Beat by $0.01
Revenue estimate$30.9M
EPS estimate-$1.02

Next report

Nov 10, 2026 (in 2 months)
Revenue estimate$3.5M
EPS estimate-$1.04

Financials

Q3 2025

Income statement

See full
Revenue$90.0K+2,900%
Operating income-$61.2M-19.7%
Net income-$56.9M-29.7%
EPS (diluted)-$1.01-27.8%

Balance sheet

See full
Cash & equivalents$48.6M-74.1%
Total debt$22.3M-10.4%
Total equity$369.0M-33.3%
Total assets$424.0M-29.8%

Cash flow

See full
Operating cash flow-$46.5M-58.2%
Free cash flow-$46.4M-48.9%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$405.84M-32.1%
Enterprise value$379.55M-12.7%
P/S3,382×-13,218×

Profitability

See full
Operating margin-191,982.5%-71,203pp
Net margin-174,314.2%-62,763pp
FCF margin-154,209.2%-53,057pp

Returns & leverage

See full
Return on equity-45.4%+29.8pp
Debt / equity0.1×0.0×
Current ratio8.4×-8.9×

Segments

By product

See full
Collaboration And License Revenue$90.0K+2,900%

FAQ

When did 4D Molecular Therapeutics report Q3 2025 earnings?
4D Molecular Therapeutics (FDMT) reported Q3 2025 earnings on November 10, 2025 before market open.
What were 4D Molecular Therapeutics's Q3 2025 revenue and EPS?
4D Molecular Therapeutics reported revenue of $90.0K and eps of $-1.01 for Q3 2025.
Did 4D Molecular Therapeutics beat estimates in Q3 2025?
Revenue missed the consensus estimate of $30.9M by $30.8M. EPS beat the consensus estimate of $-1.02 by $0.01.
How did 4D Molecular Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 2900.0% from $3.0K a year earlier and eps declined 27.8% from $-0.79.
Where can I find 4D Molecular Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-272286) and the 10-Q periodic report (0001193125-25-273343) directly on SEC EDGAR. The filing index links above go to sec.gov.